|
1
|
Testa JR, Cheung M, Pei J, Below JE, Tan
Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al: Germline
BAP1 mutations predispose to malignant mesothelioma. Nat Genet.
43:1022–1025. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baas P, Scherpereel A, Nowak AK, Fujimoto
N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et
al: First-line nivolumab plus ipilimumab in unresectable malignant
pleural mesothelioma (CheckMate 743): A multicentre, randomised,
open-label, phase 3 trial. Lancet. 397:375–386. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kulangara K, Zhang N, Corigliano E,
Guerrero L, Waldroup S, Jaiswal D, Ms MJ, Shah S, Hanks D, Wang J,
et al: Clinical utility of the combined positive score for
programmed death ligand-1 expression and the approval of
pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med.
143:330–337. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carbone M, Yang H, Pass HI, Krausz T,
Testa JR and Gaudino G: BAP1 and Cancer. Nat Rev Cancer.
13:153–159. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Novelli F, Yoshikawa Y, Vitto VAM, Modesti
L, Minaai M, Pastorino S, Emi M, Kim JH, Kricek F, Bai F, et al:
Germline BARD1 variants predispose to mesothelioma by impairing DNA
repair and calcium signaling. Proc Natl Acad Sci USA.
121:e24052311212024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carbone M, Pass HI, Ak G, Alexander HR Jr,
Baas P, Baumann F, Blakely AM, Bueno R, Bzura A, Cardillo G, et al:
Medical and surgical care of patients with mesothelioma and their
relatives carrying germline BAP1 mutations. J Thorac Oncol.
17:873–889. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carbone M, Harbour JW, Brugarolas J,
Bononi A, Pagano I, Dey A, Krausz T, Pass HI, Yang H and Gaudino G:
Biological mechanisms and clinical significance of BAP1 mutations
in human cancer. Cancer Discov. 10:1103–1120. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu J, Wang H, Ricketts CJ, Yang Y, Merino
MJ, Zhang H, Shi G, Gan H, Linehan WM, Zhu Y and Ye D: Germline
mutations of renal cancer predisposition genes and clinical
relevance in Chinese patients with sporadic, early-onset disease.
Cancer. 125:1060–1069. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong L, Zhang H, Zhang H, Ye Y, Cheng Y,
Li L, Wei L, Han L, Cao Y, Li S, et al: The mutation landscape of
multiple cancer predisposition genes in Chinese familial/hereditary
breast cancer families. Cancer Biol Med. 19:850–870.
2021.PubMed/NCBI
|
|
10
|
Kong W, Yang T, Wen X, Mu Z, Zhao C, Han
S, Tian J, Zhang X, Zhou T, Zhang Y, et al: Germline mutation
landscape and associated clinical characteristics in Chinese
patients with renal cell carcinoma. Front Oncol. 11:7375472021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nasu M, Emi M, Pastorino S, Tanji M,
Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, et al:
High Incidence of Somatic BAP1 alterations in sporadic malignant
mesothelioma. J Thorac Oncol. 10:565–576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shrestha R, Nabavi N, Lin YY, Mo F,
Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, et al: BAP1
haploinsufficiency predicts a distinct immunogenic class of
malignant peritoneal mesothelioma. Genome Med. 11:82019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ismail IH, Davidson R, Gagné JP, Xu ZZ,
Poirier GG and Hendzel MJ: Germline mutations in BAP1 impair its
function in DNA double-strand break repair. Cancer Res.
74:4282–4294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chu Q, Perrone F, Greillier L, Tu W,
Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M,
Morabito A, et al: Pembrolizumab plus chemotherapy versus
chemotherapy in untreated advanced pleural mesothelioma in Canada,
Italy, and France: A phase 3, open-label, randomised controlled
trial. Lancet. 402:2295–2306. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Louw A, Panou V, Szejniuk WM, Meristoudis
C, Chai SM, van Vliet C, Lee YCG, Dick IM, Firth T, Lynggaard LA,
et al: BAP1 loss by immunohistochemistry predicts improved survival
to first-line platinum and pemetrexed chemotherapy for patients
with pleural mesothelioma: A validation study. J Thorac Oncol.
17:921–930. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oehl K, Vrugt B, Wagner U, Kirschner MB,
Meerang M, Weder W, Felley-Bosco E, Wollscheid B, Bankov K, Demes
MC, et al: Alterations in BAP1 are associated with cisplatin
resistance through inhibition of apoptosis in malignant pleural
mesothelioma. Clin Cancer Res. 27:2277–2291. 2021. View Article : Google Scholar : PubMed/NCBI
|
